Myocardial Infarction - Pipeline Review, H2 2015 Summary Global Markets Direct s, Myocardial Infarction - Pipeline Review, H2 2015, provides an overview of the Myocardial Infarctions therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Myocardial Infarction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Infarction and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Myocardial Infarction - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Myocardial Infarction and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Myocardial Infarction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Myocardial Infarction pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myocardial Infarction - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myocardial Infarction pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Browse Complete Report with TOC @http://www.idatainsights.com/reports-landing-page.php?id=124186/myocardial-infarction-pipeline-review-h2-2015
To Get Sample Copy of Report visit @http://www.idatainsights.com/reports-landing-page.php?id=124186/myocardial-infarction-pipeline-review-h2-2015
Table of Contents
Table of Contents
2 List of Tables
7 List of Figures
10 Global Markets Direct Report Coverage
10 Myocardial Infarction Overview
11 Therapeutics Development
12 Pipeline Products for Myocardial Infarction - Overview
12 Pipeline Products for Myocardial Infarction - Comparative Analysis
13 Myocardial Infarction - Therapeutics under Development by Companies
14 Myocardial Infarction - Therapeutics under Investigation by Universities/Institutes
20 Myocardial Infarction - Pipeline Products Glance
21 Late Stage Products
21 Clinical Stage Products
22 Early Stage Products
23 Unknown Stage Products
24 Myocardial Infarction - Products under Development by Companies
25 Myocardial Infarction - Products under Investigation by Universities/Institutes 31 Myocardial Infarction - Companies Involved in Therapeutics Development
33 Alligator Bioscience AB 33 Amarantus Bioscience Holdings, Inc.
34 Angion Biomedica Corp.
35 Aprogen, Inc.
36 APT Therapeutics, Inc.
37 AstraZeneca Plc
38 Athersys, Inc.
39 Bayer AG
40 Bharat Biotech International Limited
41 BioLineRx, Ltd.
42 Biscayne Pharmaceuticals, Inc.
45 ChemoCentryx, Inc.
46 Compugen Ltd.
47 CSL Limited 48 FibroGen, Inc.
49 Fina Biotech
50 Hadasit Medical Research Services & Development Ltd
51 Human Stem Cells Institute
52 HUYA Bioscience International, LLC
53 Immune Pharmaceuticals Inc.
54 Inbiopro Solutions Pvt. Ltd.
55 Juventas Therapeutics, Inc.
56 Laboratoires Pierre Fabre SA
57 Lacer, S.A.
58 Lee's Pharmaceutical Holdings Limited
59 LegoChem Biosciences, Inc
60 LG Life Sciences, Ltd.
61 Medestea Research & Production S.p.A.
62 Mesoblast Limited
63 miRagen Therapeutics, Inc.
64 NeuroVive Pharmaceutical AB
65 Omeros Corporation 66 Omni Bio Pharmaceutical Inc. 67 Otsuka Holdings Co., Ltd. 68 Polyphor Ltd. 69 Quantum Genomics SA
70 Recardio GmbH
71 Remedy Pharmaceuticals, Inc.
72 Serodus ASA
73 STELIS Biopharma Pvt. Ltd.
74 Stemedica Cell Technologies, Inc.
75 Stempeutics Research Private Limited
76 TaiGen Biotechnology Co., Ltd.
77 Targazyme, Inc.
78 The International Biotechnology Center (IBC) Generium
79 TiGenix NV 80 Vicore Pharma AB 81 Virocan Therapeutics Private Limited
82 Yuyu Pharma, Inc. 83 Zealand Pharma A/S
84 Zydus Cadila Healthcare Limited
85 Myocardial Infarction - Therapeutics Assessment
86 Assessment by Monotherapy Products
86 Assessment by Target
87 Assessment by Mechanism of Action 91 Assessment by Route of Administration
94 Assessment by Molecule Type 96 Drug Profiles 98 ADC-1004 - Drug Profile
98 Alda-1 - Drug Profile 99 Alpha-1 Antitrypsin - Drug Profile
100 alteplase biosimilar - Drug Profile
102 AMRS-001 - Drug Profile
103 AmVimi-007 - Drug Profile
105 ANG-4011 - Drug Profile
106 AP-102 - Drug Profile
107 APT-102 - Drug Profile
108 balixafortide - Drug Profile
110 Biosimilar 3 for Rheumatoid Arthritis and Acute Myocardial Infarction - Drug Profile
111 Biosimilar 4 for Acute Myocardial Infarction and Infertility - Drug Profile
112 BIS-5409 - Drug Profile
113 Bone Marrow Derived Mononuclear Cells for Cardiovascular Diseases - Drug Profile
114 burixafor - Drug Profile
116 C-21 - Drug Profile
118 C3BSGQR-3 - Drug Profile
120 C3BSGQR-4 - Drug Profile
121 CAP-1001 - Drug Profile
122 CAP-1002 - Drug Profile 123 CCX-872 - Drug Profile
125 cenderitide - Drug Profile
126 CGEN-856 - Drug Profile 128 CGEN-856S - Drug Profile
129 CIGB-500 - Drug Profile
131 CM-1 - Drug Profile
132 Cryocell - Drug Profile
134 CSL-112 - Drug Profile
135 CTX-101 - Drug Profile
137 CTX-201 - Drug Profile
139 cyclosporine - Drug Profile
140 danegaptide - Drug Profile
141 Drugs to Inhibit Alpha Myosin for Cardiovascular Disorders - Drug Profile
142 Drugs to Inhibit Sir2 Protein for Ischemic Stroke and Myocardial Infarction - Drug Profile
143 dutogliptin tartrate - Drug Profile
144 Ephrin A-1 for Myocardial Infarction - Drug Profile
146 F-573 - Drug Profile
147 Fc-Alpha-1 Antitrypsin - Drug Profile
148 FcAAT-2 - Drug Profile
149 FcAAT-3 - Drug Profile
150 FG-6874 - Drug Profile
151 Gemacell - Drug Profile
152 Gene Therapy for Acute Myocardial Infarction - Drug Profile
153 glyburide - Drug Profile
154 HBI-3802 - Drug Profile
156 HYPER-IL-6 - Drug Profile
157 IBPB-005ET - Drug Profile
158 ICG-001 - Drug Profile
159 IS-20 - Drug Profile
160 JI-38 - Drug Profile
161 JVS-100 - Drug Profile
162 JVS-200 - Drug Profile
164 KR-33028 - Drug Profile
165 LA-8045 - Drug Profile
166 LC-280126 - Drug Profile
167 Mesenchymal Stem Cells - Drug Profile
169 MGN-1374 - Drug Profile
171 MGN-6114 - Drug Profile
172 Monoclonal Antibody Conjugates to Target Mannose Receptor for Myocardial Infarction - Drug Profile
173 MPC-150IM - Drug Profile
174 MPC-25IC - Drug Profile
176 MTP-131 - Drug Profile
177 MultiStem - Drug Profile
179 NVP-019 - Drug Profile
183 Oligonucleotide for Oncology and Cardiovascular - Drug Profile
184 Oligonucleotides for Cardiometabolic Diseases and Renal diseases - Drug Profile
185 OMS-721 - Drug Profile
186 OPC-28326 - Drug Profile
188 Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases - Drug Profile
190 Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Drug Profile
191 Polyglactin 370 for Acute Myocardial Infarction - Drug Profile
192 Protein for Cardiovascular Diseases - Drug Profile
193 ProtheraCytes - Drug Profile
194 QGC-101 - Drug Profile
196 RBB-001 - Drug Profile
197 Recombinant Protein for Myocardial Infarction - Drug Profile
198 Recombinant Proteins to Agonize IGF-1R for Myocardial Infarction - Drug Profile
199 Recombinant Prourokinase - Drug Profile
200 remestemcel-L - Drug Profile
201 rivaroxaban - Drug Profile 204 RNAi Oligonucleotide for Myocardial Infarction - Drug Profile
209 RNAi Oligonucleotide for Myocardial Infarction - Drug Profile
210 SBL-004 - Drug Profile
211 SER-130 - Drug Profile
212 Small Molecule for Myocardial Infarction - Drug Profile
213 Small Molecule to Inhibit Blood Factor XIa for CAHD and Stroke - Drug Profile
214 Small Molecules for Myocardial Infarction and Inflammation - Drug Profile
215 Small Molecules to Antagonize Adenosine A2B Receptor for Asthma and Myocardial Infarction - Drug Profile
216 Small Molecules to Inhibit BAX for Myocardial Infarction - Drug Profile
217 Small Molecules to Inhibit MMP for Myocardial Infarction - Drug Profile
218 Small Molecules to Inhibit PARP for Immunology, Oncology, Cardiovascular and Metabolic Disorders - Drug Profile 219 Stem Cell Therapy for Cardiovacular Diseases - Drug Profile
220 Stem Cell Therapy for Myocardial Infarction - Drug Profile
221 Stem Cells for Acute Myocardial Infarction - Drug Profile
223 Stempeucel - Drug Profile
224 Synthetic Peptide for Cardiovascular Diseases - Drug Profile
227 THR-100 - Drug Profile 228 ticagrelor - Drug Profile
230 TZ-101 - Drug Profile
234 VN-100 - Drug Profile
236 ZK-001 - Drug Profile
237 Myocardial Infarction - Recent Pipeline Updates
239 Myocardial Infarction - Dormant Projects
308 Myocardial Infarction - Discontinued Products
315 Myocardial Infarction - Product Development Milestones
316 Featured News & Press Releases
325 Secondary Research
325 Primary Research
325 Expert Panel Validation
325 Contact Us
iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.
We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects.